Microcap Movers for Tuesday December 13, 2011

Below are highlights from Benzinga's daily coverage of microcap ecurities. Benzinga provides comprehensive, objective, and conflict-free coverage of the microcap sector in real-time at BenzingaSmallCap.com.LiveDealShares of LiveDeal (NASDAQ: LIVE), the Las Vegas provider of customer acquisition services, rose 286% Tuesday on 733 times the average daily volume. LiveDeal's 8-K filing today stated the following: On December 12, 2011, LiveDeal completed an equity financing with five unaffiliated investors for an aggregate cash purchase price of $2.0 million. The Company issued a total of 1,612,899 new shares of its common stock in connection with the transaction at a price of $1.24 per share, which was equal to the closing bid price of the common stock as reported on the NASDAQ Capital Market on the date of the transaction. As of December 12, 2011, the Company had 725,479 shares of common stock outstanding, which had a book value per share equal to approximately $1.04 based on the Company's unaudited stockholders' equity as of September 30, 2011. After giving pro forma effect to the transaction, the Company had 2,338,378 shares of common stock issued and outstanding on September 30, 2011, with a book value per share equal to approximately $1.18 based on the Company's pro forma unaudited stockholders' equity as of September 30, 2011 giving effect to the equity financing. LiveDeal shares traded in a range of $1.32 to $6.39 Tuesday, closing at $5.60.TengionShares of Tengion (NASDAQ: TNGN), the East Norriton, PA biotech company with emphasis on organ regeneration, rose 20% on slightly less on the average daily volume.Tengion is presenting this week at the TERMIS North America Annual Conference being held in Houston, TX. The company announced new data from the Company's Neo-Urinary Conduit and Neo-Kidney Augment program Tuesday.Tengion shares traded Tuesday in a range of $0.41 to $0.49 on slightly less than the average daily volume, closing at $0.49.Alexza PharmaceuticalsShares of Alexza Pharmaceuticals (NASDAQ: ALXA), the Mountain View, CA biotech company, resumed trading Tuesday after Monday's positive FDA panel vote on the company's inhaled anti-psychotic drug Adasuve. The vote was 9 to 8 for approval.When Alexza resumed trading at 7:15am Tuesday, shares spiked higher, hitting $1.14. During the regular session, Alexza shares traded in a range of $0.77 to $1.00 on 22 times the average daily volume, closing at $0.78.To get information like this on a streaming basis during the trading day, try a 100% free trial to BenzingaSmallCap.com.